![]() | |
Names | |
---|---|
IUPAC name S-[(2R)-2,3-bis[(1-oxohexadecyl)oxy]propyl]-L-cysteinylglycyl-L-asparaginyl-L-asparaginyl-L-α-aspartyl-L-α-glutamyl-L-seryl-L-asparaginyl-L-isoleucyl-L-seryl-L-phenylalanyl-L-lysyl-L-α-glutamyl-L-Lysine | |
Other names MALP-2, S-[2,3-bis(Palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK | |
Identifiers | |
3D model (JSmol) | |
Abbreviations | XGNNDESNISFKEK |
ChemSpider | |
PubChem CID | |
UNII | |
| |
| |
Properties | |
C99H167N19O30S | |
Molar mass | 2135.59 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). |
Macrophage-activating lipopeptide 2 (MALP-2) is a lipopeptide Toll-like receptor (TLR)-2 and 6 agonist. It is used in immunological research to simulate Mycoplasma bacterial infections and activate immune cells. MALP-2 holds promise as a novel vaccine adjuvant due to its activation of TLRs. [1] [2] It also promotes vascular, bone, and wound healing. [3] [4]
MALP-2 has the structure S-2,3-bis(palmityloxy)-(2R)-propyl-cysteinyl-GNNDESNISFKEK and is a post-translationally modified CGNNDESNISFKEK peptide in which in the N-terminus cysteine residue sidechain is linked to a diacylglycerol moiety where the two acyl groups are both derived from palmitic acid. [5]
MALP-2 was initially named mycoplasma-derived high-molecular-weight material (MDHM) and, as the name suggests, had originally been isolated from Mycoplasma fermentans as an amphiphilic molecule with macropage-activating properties. This discovery helped explain how Mycoplasma bacteria can provoke immune responses despite lacking a cell wall. [6] [7]